Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin

por Meczes, E L, Pearson, A D J, Austin, C A, Tilby, M J
Publicado 2002

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.

por Peng, B., Tilby, M. J., English, M. W., Price, L., Pearson, A. D., Boddy, A. V., Newell, D. R.
Publicado 1997

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer

por Willits, I, Price, L, Parry, A, Tilby, M J, Ford, D, Cholerton, S, Pearson, A D J, Boddy, A V
Publicado 2005

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells

por Roberts, D L, Williams, K J, Cowen, R L, Barathova, M, Eustace, A J, Brittain-Dissont, S, Tilby, M J, Pearson, D G, Ottley, C J, Stratford, I J, Dive, C
Publicado 2009

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

por Plummer, R, Wilson, R H, Calvert, H, Boddy, A V, Griffin, M, Sludden, J, Tilby, M J, Eatock, M, Pearson, D G, Ottley, C J, Matsumura, Y, Kataoka, K, Nishiya, T
Publicado 2011

Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours

por Veal, G J, Errington, J, Tilby, M J, Pearson, A D J, Foot, A B M, McDowell, H, Ellershaw, C, Pizer, B, Nowell, G M, Pearson, D G, Boddy, A V
Publicado 2007